Director of Product Design, Formation Bio
$211-265k
+ Equity
End-to-end medical trial solutions
Be an early applicant
End-to-end medical trial solutions
101-200 employees
Be an early applicant
$211-265k
+ Equity
101-200 employees
Company mission
To bring new treatments to patients faster and more efficiently.
Jump to section
Company mission
To bring new treatments to patients faster and more efficiently.
Our take
Clinical drug trials are lengthy and expensive, delaying the supply of vital new drugs to patients and costing lives. For Formation Bio, this is an efficiency issue - one which it hopes to solve with its end-to-end automation solution.
According to the company, its approach has teams running medical trials twice as fast and at half the cost. It's worked so well, in fact, that Formation Bio is looking to take drug development in-house.
Now a Unicorn, the company has secured heavyweights like Pfizer, Sanofi, Novartis and 23andMe as partners. Precisely how it will fare in the Big Pharma ecosystem remains to be seen, but the promise of cheaper drugs and faster innovation is certainly causing a stir in a market that has historically been resistant to both.
Kirsty
Company Specialist at Welcome to the Jungle
Company values
- Think in first principles
- Be a scientist
- Deliver care
- Champion the mission
Funding (last 2 of 3 rounds)
Jun 2024
$372m
SERIES D
Sep 2021
$156m
SERIES C
Total funding: $530.3m
This company has top investors
Leadership
Benjamine Liu
(CEO)Worked as a computational biologist at various Neurology departments, following a D.Phil in computational Biology and Psychiatry at Oxford. They are also an Advisor at Harvard Business School.
Articles
Jobs (9)
Software Engineering
People, HR, Recruitment
Operations & Strategy
Sales & Account Management